CD4 soluble gene therapy

Drug Profile

CD4 soluble gene therapy

Latest Information Update: 29 Mar 1995

Price : $50

At a glance

  • Originator Genetic Therapy; National Institutes of Health (USA)
  • Class Antivirals; Gene therapies
  • Mechanism of Action HIV envelope protein gp120 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 29 Mar 1995 Discontinued-Preclinical for HIV infections treatment in USA (Unknown route)
  • 27 Mar 1995 Preclinical development for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top